Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
<h2>Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the safety of statins mainly atorvastatin on liver as estimated by...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Shahid Beheshti University of Medical Sciences
2015-07-01
|
Series: | Novelty in Biomedicine |
Subjects: | |
Online Access: | http://journals.sbmu.ac.ir/index.php/nbm/article/view/7657 |
id |
doaj-3fe9cd1b0f7049459142582a8c9eaae2 |
---|---|
record_format |
Article |
spelling |
doaj-3fe9cd1b0f7049459142582a8c9eaae22020-11-25T01:23:21ZengShahid Beheshti University of Medical SciencesNovelty in Biomedicine2345-33462345-39072015-07-0133991025361Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective StudyRamin Talaie0Mohammad Bagher Motevallian1Department of Internal Medicine, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Internal Medicine, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran<h2>Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the safety of statins mainly atorvastatin on liver as estimated by liver aminotransferase assay.</h2><p><strong>M</strong><strong>aterials and Methods: </strong>Patients with indication of atorvastatin were included the study. As a before and after study all the patients underwent serum level measurement of aminotransferases at the beginning and after three month of taking the drug.</p><p><strong>R</strong><strong>es</strong><strong>ults and Conclusion: </strong>HMG-COA reductase as atorvastatin should be safe in different doses 20,40 and 80 mg in patient with hyperlipidemia with and without cardiac disease without significant hepatotoxicity.</p>http://journals.sbmu.ac.ir/index.php/nbm/article/view/7657Keywords: HMGG-COA reductase, hepatotoxicity, statins, atorvastatin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ramin Talaie Mohammad Bagher Motevallian |
spellingShingle |
Ramin Talaie Mohammad Bagher Motevallian Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study Novelty in Biomedicine Keywords: HMGG-COA reductase, hepatotoxicity, statins, atorvastatin |
author_facet |
Ramin Talaie Mohammad Bagher Motevallian |
author_sort |
Ramin Talaie |
title |
Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study |
title_short |
Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study |
title_full |
Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study |
title_fullStr |
Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study |
title_full_unstemmed |
Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study |
title_sort |
evaluation of atorvastatin safety on liver function tests, a prospective study |
publisher |
Shahid Beheshti University of Medical Sciences |
series |
Novelty in Biomedicine |
issn |
2345-3346 2345-3907 |
publishDate |
2015-07-01 |
description |
<h2>Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the safety of statins mainly atorvastatin on liver as estimated by liver aminotransferase assay.</h2><p><strong>M</strong><strong>aterials and Methods: </strong>Patients with indication of atorvastatin were included the study. As a before and after study all the patients underwent serum level measurement of aminotransferases at the beginning and after three month of taking the drug.</p><p><strong>R</strong><strong>es</strong><strong>ults and Conclusion: </strong>HMG-COA reductase as atorvastatin should be safe in different doses 20,40 and 80 mg in patient with hyperlipidemia with and without cardiac disease without significant hepatotoxicity.</p> |
topic |
Keywords: HMGG-COA reductase, hepatotoxicity, statins, atorvastatin |
url |
http://journals.sbmu.ac.ir/index.php/nbm/article/view/7657 |
work_keys_str_mv |
AT ramintalaie evaluationofatorvastatinsafetyonliverfunctiontestsaprospectivestudy AT mohammadbaghermotevallian evaluationofatorvastatinsafetyonliverfunctiontestsaprospectivestudy |
_version_ |
1725122738116362240 |